Sources: 1BitterDB, 4ClinicalTrials, 7Cochrane Library, 10DGIdb, 14DrugBank, 29HMDB, 33IUPHAR, 46NDF-RT, 50Novoseek, 56PharmGKB, 68UMLSSee all MalaCards sources |
Drugs for Steatorrhea (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB): (show all 29)
| id | | Name | Status | Phase | Clinical Trials | Cas Number | PubChem Id |
|---|
| 1 | | Pancrelipase | approved | Phase 4, Phase 3, Phase 2, Phase 1 | 970 | 53608-75-6 | | 1,4-alpha-D- glucan glucanohydrolase PA | Pancreatic alpha-amylase precursor Pancrelipase (amylase lipase protease) |
| | 2 | | pancreatin | | Phase 4, Phase 3, Phase 2, Phase 1 | 970 | | | | 3 | | Gastrointestinal Agents | | Phase 4, Phase 3, Phase 2, Phase 1 | 8402 | | | | 4 | | Omeprazole | approved, investigational, vet_approved | Phase 3 | 348 | 73590-58-6 | 4594 | ( -)-Omeprazole (-)-Omeprazole (S)-(-)-Omeprazole (S)-Omeprazole 119141-89-8 131959-78-9 172964-80-6 2,3,5-Trimethylpyridine/Omeprazole 2-(((3,5-Dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1H-benzimidazole 2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1H-benzimidazole 5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole 5-Methoxy-2[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole 6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole 73590-58-6 AC-401 AC1L1IIJ AGI-010 AKOS005066653 AULCER Antra Antra MUPS Audazol Aulcer Axagon BIDD:GT0189 BPBio1_000425 BRD-A55962179-001-04-9 BSPBio_000385 Belmazol Bio-0888 C07324 CAS-73590-58-6 CCRIS 7099 CHEBI:519601 CHEBI:7772 CHEMBL1503 CID4594 CPD000058847 Ceprandal D00455 DB00338 DB00736 DM-3458 Danlox Demeprazol Desec Dizprazol Dudencer Elgam Emeproton Emilok Epirazole Erbolin Esomeprazole Esomperazole Esopral Exter Gasec Gastrimut Gastroloc Gibancer H 168-68 H 168/68 H-168/68 H168/68 HMS1528I05 HMS1569D07 HMS2052G17 HMS2090E16 HMS2090F11 HSDB 3575 I06-0705 IDI1_032523 Indurgan Inhibitron Inhipump LS-7629 Lensor Logastric Lomac Losec Losec, Omesec, Prilosec, Zegerid, Omeprazole Lucen MLS000069373 MLS001076112 MLS001424148 Maybridge4_002645 Mepral Miol Miracid MolPort-003-666-741 MolPort-003-807-515 MolPort-003-849-702 Mopral Morecon NCGC00016925-01 | NCGC00016925-02 NCGC00021522-03 NCGC00021522-04 NCGC00021522-05 Nexiam Nexium Nexium IV Nilsec Nopramin Nuclosina O0359 O104_SIGMA OMEP OMP OMZ Ocid Olexin Olit Omapren Omebeta Omebeta 20 Omed Omegast Omepradex Omepral Omeprazol Omeprazol [INN-Spanish] Omeprazole Omeprazole (JAN/USP/INN) Omeprazole Pellets Omeprazole [USAN:INN:BAN:JAN] Omeprazole delayed-release Omeprazole magnesium Omeprazolum Omeprazolum [INN-Latin] Omeprazon Omeprazone Omeprol Omesek Omez Omezol Omezolan Omid Omisec Omizac Ompanyt Ortanol Osiren Ozoken Paprazol Parizac Pepticum Pepticus Peptilcer Prazentol Prazidec Prazolit Prestwick0_000493 Prestwick1_000493 Prestwick2_000493 Prestwick3_000493 Prestwick_808 Prilosec Prilosec (TN) Prilosec OTC Procelac Proclor Prysma Ramezol Regulacid Result S1389_Selleck SAM001246900 SAN-15 SMR000058847 SPBio_002306 STK623746 Sanamidol Secrepina TL8005099 Tedec Ulceral UNII-KG60484QX9 UPCMLD-DP075 UPCMLD-DP075:001 Ulceral Ulcesep Ulcometion Ulcozol Ulcsep Ulsen Ultop Ulzol Victrix Zefxon Zegerid Zepral Zimor Zoltum esomeprazol omeprazole |
| | 5 | | Proton pump inhibitors | | Phase 3 | 1123 | | | | | 6 | | Antacids | | Phase 3 | 1842 | | | | 7 | | Anti-Ulcer Agents | | Phase 3 | 1842 | | | | 8 | | Pharmaceutical Solutions | | Phase 2, Phase 3 | 8192 | | | | 9 | | Menadione | approved, nutraceutical | Phase 1 | 239 | 58-27-5 | 4055 | 03AAE1E9-B215-45AF-976C-91E61894A467 1,4-Naphthalenedione, 2-methyl-, radical ion(1-) 2-Methyl-1,4-Naphthalenedione 2-Methyl-1,4-naftochinon 2-Methyl-1,4-naftochinon [Czech] 2-Methyl-1,4-naphthalendione 2-Methyl-1,4-naphthalenedione 2-Methyl-1,4-naphthochinon 2-Methyl-1,4-naphthochinon [German] 2-Methyl-1,4-naphthodione 2-Methyl-1,4-naphthoquinone 2-Methylnaphthoquinone 2-methyl-1,4-naphthoquinone, 5 2-methylnaphthalene-1,4-dione 3-Methyl-1,4-naphthoquinone 34524-96-4 47775_SUPELCO 58-27-5 72060-21-0 AC1L1HBA AC1Q2HB3 AI3-14700 AKOS004910447 ARONIS24154 Aquakay Aquinone BB_NC-2319 BIDD:ER0556 BPBio1_000592 BSPBio_000538 Bio1_000471 Bio1_000960 Bio1_001449 C05377 C11H8O2 CAS-58-27-5 CCRIS 6672 CHEBI:28869 CHEMBL590 CID4055 CPD-3766 D02335 DB00170 DivK1c_000080 DivK1c_006287 EINECS 200-372-6 HMS1569K20 HMS1921P06 HMS2092F12 HMS500D22 HSDB 3354 Hemodal I14-2821 IDI1_000080 InChI=1/C11H8O2/c1-7-6-10(12)8-4-2-3-5-9(8)11(7)13/h2-6H,1H Juva-K K-Thrombyl K-Vitan KBio1_000080 KBio1_001231 KBio2_001708 KBio2_002527 KBio2_004276 KBio2_005095 KBio2_006844 KBio2_007663 KBio3_003005 KBioGR_000984 KBioGR_002527 KBioSS_001708 KBioSS_002535 Kaergona Kanone Kappaxan Kappaxan (VAN) Kappaxin Kappaxin (TN) Karcon Kareon Kativ-G Kayklot Kaykot | Kaynone Kayquinone Kipca Kipca, oil soluble Kipca-Oil Soluble Klottone Koaxin Kolklot LS-95653 LS-95654 M0373 M5625_SIGMA M9429_SIGMA MLS000069420 MLS001148443 MNQ Memodol Menadion Menadione Menadione (K3) Menadione (USP) Menadione [USAN:BAN] Menadione semiquinone Menadionum Menaphthene Menaphthon Menaphthone Menaphtone Menaquinone Menaquinone 0 Menaquinone O Methyl-1,4-naphthalenedione Methyl-1,4-naphthoquinone Methylnaphthoquinone Mitenon Mitenone MolPort-001-766-699 NCGC00016258-01 NCGC00094978-01 NCGC00094978-02 NCI60_003945 NCIMech_000105 NINDS_000080 NSC 4170 NSC4170 Panosine Prestwick0_000459 Prestwick1_000459 Prestwick2_000459 Prestwick3_000459 Prestwick_313 Prokayvit QTL1_000056 S1949_Selleck SMR000059102 SMR000653532 SPBio_001267 SPBio_002477 SPECTRUM1502254 SpecPlus_000191 Spectrum2_001194 Spectrum4_000722 Spectrum5_001764 Spectrum_001228 Synkay Thyloquinone UNII-723JX6CXY5 Usaf ek-5185 VK3 Vicasol Vitamin K 3 Vitamin K0 Vitamin K2 Vitamin K2(0) Vitamin K3 Vitamin K3 : 2-Methyl-1,4-naphthoquinone Vitamin K3: 1,4-Dihydro-1,4-dioxo-2-methylnaphthalene Vitamin-?K3 WLN: L66 BV EVJ C1 ZINC00001677 cMAP_000077 menadione nchembio.109-comp5 | |
| | 10 | | Phytonadione | approved, Nutraceutical | Phase 1 | 239 | 84-80-0 | 4812, 5284607 | .alpha.-Phylloquinone 1,4-Naphthalenedione, 2-methyl-3-((2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecenyl)-, radical ion(1-) 10485-69-5 11104-38-4 15973-57-6 2', 3'-trans-Vitamin K1 2',3'-trans-Vitamin K1 2-(3,7,11,15-Tetramethylhexadec-2-enyl)-3-methylnaphthalene-1,4-dione 2-METHYL-3-PHYTYL-14-NAPHTHOQUINONE 2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalened- ione 2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione 2-Methyl-3-(3,7,11,15-tetramethylhexadec-2-enyl)-1,4-naphthoquinone 2-Methyl-3-[(2e)-3,7,11,15-tetramethyl-2-hexadecenyl]naphthoquinone 2-Methyl-3-phythyl-1,4-naphthochinon 2-Methyl-3-phytyl-1,4-naphthochinon 2-Methyl-3-phytyl-1,4-naphthochinon [German] 2-Methyl-3-phytyl-1,4-naphthoquinone 2-methyl-3-(3,7,11,15-tetramethylhexadec-2-en-1-yl)naphthalene-1,4-dione 2-methyl-3-[(E)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione 27696-10-2 3-Phytylmenadione 50926-17-5 84-80-0 AC1NQX34 AC1Q6B3J AR-1E3503 Antihemorrhagic vitamin Aqua mephyton Aqua-Mephytin Aquamephyton C02059 C31H46O2 CID5280483 Combinal K1 D00148 DB01022 EINECS 201-564-2 EINECS 234-330-3 EINECS 279-833-9 Fitomenadiona Fitomenadiona [INN-Spanish] Fitomenadione Fitomenadione [DCIT] HSDB 3162 K-Ject Kativ N Kephton | Kinadion Konakion LS-94617 LT00452032 MLS001332659 MLS001332660 Mephyton Mephyton (TN) MolPort-001-785-978 Mono-Kay Monodion NCGC00159423-02 NSC 270681 NSC270681 P0642 Phyllochinon Phyllochinon [German] Phyllochinonum Phylloquinone Phylloquinone (8CI) Phythyl-menadion Phythyl-menadion (GERMAN) Phytomenadione Phytomenadione (INN) Phytomenadionum Phytomenadionum [INN-Latin] Phytonadione Phytonadione (JP15/USP) Phytonadione [USAN:JAN] Phytonadionum Phytylmenadione SMR000059144 ST075162 Synthex P UNII-A034SE7857 VITAMIN K VITAMIN K1 Vitamin K Vitamin K 1 Vitamin K1 Vitamin K1 (TN) Vitamin K1 (VAN) Vitamin K1 (generic) Vitamin K1(20) alpha-Phylloquinone phyllohydroquinone phytonadione trans-Phylloquinone α-phylloquinone |
| | 11 | | Trace Elements | | Phase 1 | 6001 | | | | 12 | | Micronutrients | | Phase 1 | 6001 | | | | 13 | | Antifibrinolytic Agents | | Phase 1 | 484 | | | | 14 | | Coagulants | | Phase 1 | 1500 | | | | 15 | | Hemostatics | | Phase 1 | 1443 | | | | 16 | | Vitamins | | Phase 1 | 5282 | | | | 17 | | Vitamin K | Nutraceutical | Phase 1 | 240 | | | | 18 | | naphthoquinone | Nutraceutical | Phase 1 | 239 | | | | 19 | | Menaquinone | Nutraceutical | Phase 1 | 239 | | | | 20 | | Nicotine | approved | | 1103 | 54-11-5 | 942, 89594 | (− (+)-Nicotine (-)-3-(1-Methyl-2-pyrrolidyl)pyridine (-)-3-(N-Methylpyrrolidino)pyridine (-)-Nicotine (-)-Nicotine solution (2S) 3-(1-Methyl-pyrrolidin-2-yl)-pyridine (R)-3-(1-Methyl-2-pyrrolidinyl)pyridine (R,S)-Nicotine (S)-(-)-NICOTINE, 3-[(2S)-1-METHYL-2-PYRROLIDINYL] PYRIDINE (S)-(-)-Nicotine (S)-(−)-nicotine (S)-3-(1-methylpyrrolidin-2-yl)pyridine (S)-3-(N-methylpyrrolidin-2-yl)pyridine (S)-Nicotine (−)-nicotine )-1-Methyl-2-(3-pyridyl)pyrrolidine )-Nicotine )-Nicotine solution 1-Methyl-2-(3-pyridal)-Pyrrolidine 1-Methyl-2-(3-pyridal)-pyrrolidene 1-Methyl-2-(3-pyridiyl)pyrrolidine 1-Methyl-2-(3-pyridyl)pyrrolidine 1uw6 2'-beta-H-Nicotine 3-(1-Methyl-2-pyrollidinyl)pyridine 3-(1-Methyl-2-pyrrolidinyl)-Pyridine 3-(1-Methyl-2-pyrrolidinyl)pyridine 3-(1-Methylpyrrolidin-2-yl)pyridine 3-(2-(N-methylpyrrolidinyl))pyridine 3-(N-Methylpyrollidino)pyridine 3-(N-Methylpyrrolidino)pyridine 3-(N-methylpyrollidino)pyridine 3-N-Methylpyrrolidine 3-[(2S)-1-methylpyrrolidin-2-yl]pyridine 36733_FLUKA 36733_RIEDEL 434F7990-3240-4A43-ACEC-E6CC1E495FA0 46343_FLUKA 46343_RIEDEL 54-11-5 AC1L3I79 AC1Q3ZOC AI3-03424 BB_NC-0777 BIDD:GT0599 BRD-K05395900-322-02-1 Black Leaf Black Leaf 40 C00745 CCRIS 1637 CHEBI:17688 CHEMBL3 CID89594 CPD000059074 Campbell's Nico-Soap Caswell No. 597 Commit D-Nicotine D03365 DL-tetrahydronicotyrine Destruxol Destruxol Orchid Spray EINECS 200-193-3 ENT 3,424 EPA Pesticide Chemical Code 056702 Emo-Nik Flux Maag Fumeto bac Fumetobac HSDB 1107 Habitrol Habitrol (TN) L(-)-nicotine L(−)-nicotine L-3-(1-Methyl-2-pyrrolidyl)pyridine | L-Nicotine LS-202 MLS001055457 MLS001335905 Mach-Nic Methyl-2-pyrrolidinyl)pyridine Micotine MolPort-000-744-731 N3876_SIGMA N5511_FLUKA N5511_SIGMA NCGC00090693-01 NCGC00090693-02 NCGC00090693-03 NCGC00090693-04 NCGC00090693-05 NCGC00090693-06 NCGC00090693-07 NCT NICOTINE AND SALTS NSC 5065 NSC97238 Niagara P.A. Dust Nic-Sal Nico-Dust Nico-Fume Nicocide Nicoderm Nicoderm Cq Nicoderm Patch Nicorette Nicorette Plus Nicotin Nicotina Nicotina [Italian] Nicotine Nicotine (USP) Nicotine (compounds related to) Nicotine Alkaloid Nicotine Patch Nicotine Polacrilex Nicotine [BSI:ISO] Nicotine [UN1654] Nicotine [UN1654] [Poison] Nicotine [USAN] Nicotrol Nicotrol Inhaler Nicotrol Ns Nictoine patch Nikotin Nikotin [German] Nikotyna Nikotyna [Polish] Ortho N-4 Dust Ortho N-5 Dust PDSP1_000113 PDSP1_000465 PDSP2_000463 PDSP2_000555 Prostep R)-(+)-Nicotine RCRA waste no. P075 RCRA waste number P075 SAM002564224 SDCCGMLS-0066911.P001 SMR000059074 Tendust Transdermal Nicotine UN1654 a -N-Methylpyrrolidine a-N-Methylpyrrolidine alpha-N-Methylpyrrolidine beta-Pyridyl-alpha-N-methyl pyrrolidine beta-Pyridyl-alpha-N-methylpyrrolidine bmse000105 delta-Nicotine nicotine nicotine replacement patch |
| | 21 | | Teriparatide | approved, investigational | | 137 | 52232-67-4 | 16133850 | 52232-67-4 D06078 Forteo Forteo (TN) | TERIPARATIDE Teriparatide (USAN/INN) Teriparatide (genetical recombination) Teriparatide (genetical recombination) (JAN) Teriparatide recombinant human | |
| | 22 | | glucocorticoids | | | 5103 | | | | 23 | | vitamin d | | | 1724 | | | | 24 | | Calcium, Dietary | | | 5713 | | | | 25 | | Bone Density Conservation Agents | | | 3376 | | | | 26 | | Antibodies | | | 6394 | | | | 27 | | Immunoglobulins | | | 6394 | | | | 28 | | Bile Acids and Salts | | | 106 | | | | 29 | | Cholic Acids | | | 11 | | |
Interventional clinical trials: (show all 27)
| id | Name | Status | NCT ID | Phase |
|---|
| 1 | Control of Steatorrhea in Participants With Cystic Fibrosis and Exocrine Pancreatic Insufficiency | Completed | NCT01327703 | Phase 4 | | 2 | Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea | Completed | NCT00572975 | Phase 4 | | 3 | Enzyme Suppletion in Exocrine Pancreatic Dysfunction | Completed | NCT01430234 | Phase 4 | | 4 | Pancreatic Enzyme Suppletion in Pancreatic Cancer | Withdrawn | NCT01401387 | Phase 4 | | 5 | Safety and Efficacy Study of Viokase® 16 for the Correction of Steatorrhea | Completed | NCT00559364 | Phase 3 | | 6 | Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF) | Completed | NCT00880100 | Phase 3 | | 7 | Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis | Completed | NCT00432861 | Phase 3 | | 8 | Safety and Efficacy Study of ULTRASE® MT20 in Participants With Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (PI) | Completed | NCT00408317 | Phase 3 | | 9 | A Study of the Efficacy and Tolerability of Pancrelipase Microtablet (MT) Capsules for the Treatment of Cystic Fibrosis-dependent Exocrine Pancreatic Insufficiency | Completed | NCT00662675 | Phase 3 | | 10 | Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI) | Completed | NCT00513682 | Phase 3 | | 11 | Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation | Active, not recruiting | NCT01967888 | Phase 2, Phase 3 | | 12 | Creon in HIV Patients With Steatorrhea | Terminated | NCT00623025 | Phase 3 | | 13 | Effectiveness of Pancreatic Enzymes in Patients Pancreatic Insufficient: Comparison of Two Drugs | Withdrawn | NCT01228643 | Phase 3 | | 14 | An Effectiveness, Safety, and Palatability Study of Pancrelipase Microtablets in Infants and Toddlers With Cystic Fibrosis and Fat Malabsorption | Completed | NCT00217204 | Phase 2 | | 15 | Tolerance and Digestibility of a New Formula in Healthy Infants | Completed | NCT01184378 | Phase 2 | | 16 | An Open-Label Study to Evaluate the Intraduodenal Delivery of Enzymes From Administration of VIOKASE16 in Exocrine Pancreatic Insufficiency (EPI) | Completed | NCT00559052 | Phase 2 | | 17 | A Study of the Enzyme Activity and Safety of Pancrelipase in Patients With Severe Exocrine Pancreatic Insufficiency (EPI) | Completed | NCT00676702 | Phase 1 | | 18 | Randomized Study of Pancrelipase With Bicarbonate (PANCRECARB) Capsules in Reducing Steatorrhea in Patients With Cystic Fibrosis | Completed | NCT00006063 | | | 19 | Incidence and Risk Factor of Post-ERCP Pancreatitis in Chronic Pancreatitis | Completed | NCT02781987 | | | 20 | Horton & Maizy Pilot Study for Resistant to Starch | Completed | NCT01338571 | | | 21 | Timing of Surgical Intervention After Percutaneous Catheter Drainage in STEP UP Approach for Severe Acute Pancreatitis | Completed | NCT01527084 | | | 22 | Celiac Disease Diagnosis in Patients With Weakly Positive Serum Anti-Transglutaminase: Duodenal Anti-Endomysium Assay. | Recruiting | NCT02242123 | | | 23 | Study of the Diagnostic Value of Stable Calcium Isotope Profiling in Bone and Calcium Disorders | Recruiting | NCT02252679 | | | 24 | Effect of Potato Fiber on Appetite and Fecal Fat Excretion | Active, not recruiting | NCT02957318 | | | 25 | Comparison of Feasibility Between Internal and External Pancreatic Drainage in Pancreaticoduodenectomy | Active, not recruiting | NCT01023594 | | | 26 | The FOCCUS Study: "Focusing on Cancers Chemotherapys' Untreated Symptoms" | Active, not recruiting | NCT02121626 | | | 27 | The Replace Registry | Not yet recruiting | NCT03115086 | |
Cochrane evidence based reviews: steatorrhea
|
